132 related articles for article (PubMed ID: 35597299)
21. Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study.
Kamaraj B; Bogaerts A
PLoS One; 2015; 10(8):e0134638. PubMed ID: 26244575
[TBL] [Abstract][Full Text] [Related]
22. Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells.
Abu El Maaty MA; Strassburger W; Qaiser T; Dabiri Y; Wölfl S
Mol Carcinog; 2017 Nov; 56(11):2486-2498. PubMed ID: 28618116
[TBL] [Abstract][Full Text] [Related]
23. The Oncological Effect of Mutant p53 on the Metastatic Phenotype of Gastric Cancer Cells.
Kitagawa H; Hiraki M; Namba T; Baba K; Miyake S; Ito K; Tanaka T; Noshiro H
Anticancer Res; 2023 Nov; 43(11):4887-4895. PubMed ID: 37909947
[TBL] [Abstract][Full Text] [Related]
24. The expression of the P2Y
Molle CM; Arguin G; Jemfer C; Placet M; Dagenais Bellefeuille S; Gendron FP
Biochem Biophys Res Commun; 2020 Apr; 524(4):798-802. PubMed ID: 32037085
[TBL] [Abstract][Full Text] [Related]
25. Identification of spliced variants of the proto-oncogene HDM2 in colorectal cancer.
Yu Z; Zhang B; Cui B; Wang Y; Han P; Wang X
Cancer; 2012 Feb; 118(4):1110-8. PubMed ID: 21761395
[TBL] [Abstract][Full Text] [Related]
26. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway.
Zhang Y; Wolf GW; Bhat K; Jin A; Allio T; Burkhart WA; Xiong Y
Mol Cell Biol; 2003 Dec; 23(23):8902-12. PubMed ID: 14612427
[TBL] [Abstract][Full Text] [Related]
27. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers.
Solomon H; Dinowitz N; Pateras IS; Cooks T; Shetzer Y; Molchadsky A; Charni M; Rabani S; Koifman G; Tarcic O; Porat Z; Kogan-Sakin I; Goldfinger N; Oren M; Harris CC; Gorgoulis VG; Rotter V
Oncogene; 2018 Mar; 37(12):1669-1684. PubMed ID: 29343849
[TBL] [Abstract][Full Text] [Related]
28. Ribosomal protein S15A promotes malignant transformation and predicts poor outcome in colorectal cancer through misregulation of p53 signaling pathway.
Chen J; Wei Y; Feng Q; Ren L; He G; Chang W; Zhu D; Yi T; Lin Q; Tang W; Xu J; Qin X
Int J Oncol; 2016 Apr; 48(4):1628-38. PubMed ID: 26847263
[TBL] [Abstract][Full Text] [Related]
29. An N
Uddin MB; Roy KR; Hosain SB; Khiste SK; Hill RA; Jois SD; Zhao Y; Tackett AJ; Liu YY
Biochem Pharmacol; 2019 Feb; 160():134-145. PubMed ID: 30578766
[TBL] [Abstract][Full Text] [Related]
30. Ultraslow oligomerization equilibria of p53 and its implications.
Natan E; Hirschberg D; Morgner N; Robinson CV; Fersht AR
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14327-32. PubMed ID: 19667193
[TBL] [Abstract][Full Text] [Related]
31. Lipoic Acid Synergizes with Antineoplastic Drugs in Colorectal Cancer by Targeting p53 for Proteasomal Degradation.
Neitzel C; Seiwert N; Göder A; Diehl E; Weber C; Nagel G; Stroh S; Rasenberger B; Christmann M; Fahrer J
Cells; 2019 Jul; 8(8):. PubMed ID: 31366086
[TBL] [Abstract][Full Text] [Related]
32. Coexpression and nuclear colocalization of metastasis-promoting protein S100A4 and p53 without mutual regulation in colorectal carcinoma.
Berge G; Costea DE; Berg M; Rasmussen H; Grotterød I; Lothe RA; Mælandsmo GM; Flatmark K
Amino Acids; 2011 Oct; 41(4):875-84. PubMed ID: 20191297
[TBL] [Abstract][Full Text] [Related]
33. LUCAT1 promotes colorectal cancer tumorigenesis by targeting the ribosomal protein L40-MDM2-p53 pathway through binding with UBA52.
Zhou Q; Hou Z; Zuo S; Zhou X; Feng Y; Sun Y; Yuan X
Cancer Sci; 2019 Apr; 110(4):1194-1207. PubMed ID: 30690837
[TBL] [Abstract][Full Text] [Related]
34. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.
Puca R; Nardinocchi L; Porru M; Simon AJ; Rechavi G; Leonetti C; Givol D; D'Orazi G
Cell Cycle; 2011 May; 10(10):1679-89. PubMed ID: 21508668
[TBL] [Abstract][Full Text] [Related]
35. RSL1D1 knockdown induces ferroptosis and mediates ferrous iron accumulation in senescent cells by inhibiting FTH1 mRNA stability.
Jin Y; Zhao L; Wang S; Zhang X; Quan J; Lin Z; Piao J
Carcinogenesis; 2023 May; 44(2):129-142. PubMed ID: 36913375
[TBL] [Abstract][Full Text] [Related]
36. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis.
Lu X; Liu DP; Xu Y
Oncogene; 2013 Jun; 32(23):2900-6. PubMed ID: 22824795
[TBL] [Abstract][Full Text] [Related]
37. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
[TBL] [Abstract][Full Text] [Related]
38. LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation.
Zeng K; Chen X; Hu X; Liu X; Xu T; Sun H; Pan Y; He B; Wang S
Oncogene; 2018 Oct; 37(41):5534-5551. PubMed ID: 29899406
[TBL] [Abstract][Full Text] [Related]
39. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
[TBL] [Abstract][Full Text] [Related]
40. Dynamics and Molecular Mechanisms of p53 Transcriptional Activation.
Offutt TL; Ieong PU; Demir Ö; Amaro RE
Biochemistry; 2018 Nov; 57(46):6528-6537. PubMed ID: 30388364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
